|
|
|
25.09.25 - 23:48
|
XFRA: DIVIDEND/INTEREST INFORMATION - 29.09.2025 - JP3463000004 (XETRA)
|
|
|
Das Instrument TKD JP3463000004 TAKEDA PHARM.CO.LTD. EQUITY wird cum Dividende/Zinsen gehandelt am 26.09.2025 und ex Dividende/Zinsen am 29.09.2025
The instrument TKD JP3463000004 TAKEDA PHARM.CO.LTD. EQUITY has its pre-dividend/interest day on 26.09.2025 and its ex-dividend/interest day on 29.09.2025...
|
|
|
|
|
24.09.25 - 00:12
|
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries (Business Wire)
|
|
|
More Than 20,000 Takeda Employees Across 80 Countries and Regions Voted to Select the FY2025 New Awardees: International Medical Corps (IMC), the Society of Critical Care Medicine (SCCM), the United Nations Office for Project Services (UNOPS) Bangladesh, and Vitamin Angels
Takeda's Four New Collaborations—A Commitment of JPY 4.6 Billion (Approx. USD 32.1 Million)—Boost the Total Global CSR Program Contributions to JPY 33.4 Billion (Approx. USD 238.7 Million) Across 38 Diverse Collaborations Worldwide and Extend Our Reach to an Additional 26.6 Million Direct Beneficiaries
Takeda's Global CSR Program Expects to Reach 53.7 Million People in 94 Countries by 2030
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to building climate-resilient health systems in low- and middle-income countries around the world...
|
|
|
|
|
|
|
11.09.25 - 14:48
|
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit (Business Wire)
|
|
|
− Rhonda Pacheco to Succeed Julie Kim, Who Was Appointed to Be Takeda's Next CEOCAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda's U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Directors to succeed Christophe Weber as president and Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco's appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division.
“We are thrilled to welcome Rhonda to Takeda,” said Julie Kim and Christophe Weber. “Rhonda embodies our values, and she brings a compelling blend of strategic acumen, operational excellence and people-first leadership that aligns seamlessly with the evolving needs of our U.S. ...
|
|
|
08.09.25 - 14:00
|
Takeda receives FDA approval for Vonvendi sBLA (PBR)
|
|
|
VWD is the most prevalent inherited bleeding disorder in the US, affecting over three million individuals, with both men and women equally susceptible. Vonvendi is also approved for
The post Takeda receives FDA approval for Vonvendi sBLA appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
26.08.25 - 13:03
|
Medical Affairs Leader Dr. Kirk Shepard Joins BP Logix′s Life Sciences Strategic Advisory Board (Business Wire)
|
|
|
Renowned Medical Affairs executive and MAPS co-founder Dr. Kirk Shepard steps up to help guide the next wave of digital innovation in the life sciences sector.SAN DIEGO--(BUSINESS WIRE)--#MedicalAffairs--As part of its mission to drive innovation in Medical Affairs automation, BP Logix is pleased to announce the appointment of Dr. Kirk Shepard to the company's Life Sciences Strategic Advisory Board.
Dr. Shepard is a globally recognized expert in Medical Affairs who brings more than 30 years of deep operational knowledge and thought leadership to the Advisory Board.
He currently serves as Chief Medical Officer at PDS Biotech. His prior roles include Chief Medical Officer and Head of Global Medical Affairs Oncology at Eisai, as well as senior leadership positions at Takeda, Boehringer Ingelheim, Baxter, and Baxalta.
He is also a co-founder and former President of the Medical Affairs Professional Society (MAPS), which boasts more than 15,000 members. His upcoming book, Voices of Oncology (Forbes Books, Sept...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
